Compare Global X Copper Miners ETF (COPX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Merck & Co., Inc. — how do they compare? Global X Copper Miners ETF trades at $88.53, while Merck & Co., Inc. trades at $133.9 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while Global X Copper Miners ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Global X Copper Miners ETF nearer its low. Which is the better fit depends on your goals.
| COPX | MRK | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $95.70 | $131.84 |
52-Week Low | $46.08 | $77.60 |
Market Cap | — | $321.77B |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $88.51, down 1.12% today, while maintaining a bullish technical outlook with strong moving average signals. The ETF offers exposure to copper miners benefiting from AI-driven demand for electrification infrastructure. Recent institutional buying includes 180 Wealth Advisors increasing its position by 28.1% in Q2 2026 (SEC filing, August 2026). Technical indicators show overbought RSI levels but strong trend momentum with ADX readings.
The copper mining sector faces structural demand growth from AI data center expansion and electrification trends, though mining equities currently trade at a discount to copper futures. Supply constraints and cyclical volatility present risks, but analyst sentiment remains positive for long-term exposure to copper's role in the energy transition.
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
